
(12) UK Patent Application (19) GB (11) 2 006 011 A

(21) Application No 7842473

(22) Date of filing

30 Oct 1978

(23) Claims filed

30 Oct 1978

(30) Priority data

(31) 32787/77

(32) 4 Aug 1977

(33) United Kingdom (GB)

(43) Application published

2 May 1979

(51) INT CL² A61K 45/00

(52) Domestic classification

A5B 170 180 301 30Y

380 38Y H

(56) Documents cited

GB 1106551

GB 987430

Martindale The Extra

Pharmacopoeia 27th ed

1977 pp 1011 to 1028

(58) Field of search

A5B

(71) Applicants

John Rhodes

25 Nant Fawr Road

Cyncoed

Cardiff

Wales

Brian Kenneth Evans

9 Merevale

The Common

Dinas Powis

South Glamorgan

Wales

(72) Inventors

John Rhodes

Brian Kenneth Evans

(74) Agents

W H Beck Greener & Co

(54) Carminative preparations

(57) Essential oils (including aromatic carminatives) and their active components are administered to the intestine to treat irritable colon syndrome. The oils are presented in a rectal or, preferably, enteric preparation, especially an enterically coated hard gelatine capsule. Peppermint oil is preferred.

GB 2 006 011 A

SPECIFICATION

Carminative preparations containing essential oils or their active components

5 The present invention relates to carminative preparations containing carminative essential oils (as hereinafter defined) or active components of such oils. It provides novel preparations
10 for selectively administering a carminative in the intestine.

Functional bowel disorders characterised by recurrent intestinal distension, colicky pain, and intermittent change in bowel habit are
15 common. They are frequently described as "irritable colon syndrome", which is a diagnosis arrived at after exclusion of other organic pathologies. This group of conditions may not be a single group with a simple basis of one
20 aetiological factor but it is probably the most common single clinical problem relating to disorders of the large bowel. The condition tends to be chronic, with relapses even after a time of normal health.

25 Irritable colon syndrome and certain other intestinal disorders such as diverticular disease and spastic colon could be relieved by administering to the intestine a muscle relaxant and/or antispasmodic drug. However, no
30 wholly satisfactory treatment of these disorders has been available. It is therefore an object of the present invention to provide a relatively inexpensive, easily administered and effective treatment for these disorders.

35 Essential oils (otherwise known as aethereolea) are ethereal oils obtained from plants and some of these oils have been known as medicaments since the very beginning of pharmacy. Many belong to the terpene group
40 whilst others are related to benzene derivatives. They exert a mild irritant action on the mucous membranes of the mouth and digestive tract and mild expectorants. In particular, they are used as carminatives (i.e. muscle
45 relaxant with antispasmodic effect) after meals and for the relief of gastric discomfort and of flatulent colic and also to counteract the gripping action of purgatives (see "The Extra Pharmacopoeia, 27th Edition, Martindale). Aromatic
50 carminatives are volatile substances related to essential oils and having similar carminative action and a clear distinction between aromatic carminatives and essential oils is not always drawn.

55 Accordingly, the term "essential oil" as used in this Specification includes aromatic carminatives unless the context clearly implies otherwise. The term "carminative essential oil" is used to mean those essential oils and
60 aromatic carminatives which are sufficiently non-toxic and otherwise pharmacologically acceptable for gastrointestinal use and thereby to exclude such toxic essential oils as pine and turpentine.

65 A substantially complete list of essential oils

is given at pages 1011 to 1028 of "The Extra Pharmacopoeia", Edition 27, Martindale.

When administered for their known carminative effect, the essential oils are taken orally
70 in a form which is effective in the stomach. The dose administered is limited by the irritant action of the essential oils on the mucous membranes and particularly by action on the gastrooesophageal spincter. Thus, the essential oil so administered passes into the small
75 intestine, and eventually into the colon; the amount is insufficient to produce any substantial carminative effect in the intestine and certainly insufficient for the effective treatment
80 of irritable colon syndrome, diverticular disease or spastic colon. To the best of our knowledge the possibility of using essential oils for treatment of such intestinal disorders has been dismissed, perhaps subconsciously,
85 because of the dose limitations imposed by the effect on the mucous membranes of the oesophagus and stomach and/or gastro-oesophageal spincter. The fact of the matter is that our investigations indicate that, despite the
90 long known carminative action of essential oils and the long felt need for a readily administered and effective treatment for irritable colon syndrome, there has been no previous proposal to use essential oils for inducing a carminative
95 effect in the intestine.

We have found that carminative essential oils provide a readily administered and effective treatment for irritable colon syndrome when presented as an enteric preparation or
100 as a rectal preparation. By "enteric preparation", we mean a preparation which when taken orally will pass through the stomach substantially without release of the active principle but which will release the active principle
105 in the intestine. By "rectal preparation", we mean a preparation which is specifically formulated for rectal administration and exclude any preparations suitable for oral administration. Enteric preparations and rectal preparations are well known *per se* and accordingly it should be clearly understood that the invention resides in the presentation of carminative essential oils in such preparations as
110 distinct from enteric or rectal preparations in general.
115

The present invention provides in one aspect thereof an enteric preparation (as hereinbefore defined) containing as a pharmacologically active ingredient a carminative essential
120 oil (as hereinbefore defined) or a carminative component thereof.

In a second aspect, the invention provides a rectal preparation (as hereinbefore defined) containing as a pharmacologically active ingredient a carminative essential oil (as hereinbefore defined) or a carminative component thereof.
125

The essential oil or component thereof can be obtained by extraction from a plant or can
130 be synthetically produced. The presently pre-

ferred carminatives are those containing menthol, particularly those obtained from species of *Mentha* especially peppermint oil (B.P.).

Peppermint oil (B.P.) contains 4 to 10% w/w esters calculated as menthyl acetate, not less than 44% w/w free alcohols calculated as menthol and 1 to 32% w/w ketonic compounds calculated as menthone. It is a colourless, pale yellow or greenish-yellow liquid obtained by distillation and, if necessary, subsequent rectification from the fresh flowering tops of the plant *Mentha × piperita* (Labiatae). Non-limiting examples of other carminative essential oils and carminative components thereof are benzaldehyde, camphor, carvone, cineole, cinnamaldehyde, cinnamon, citral, clove, eucalyptus, eugenol, linalol, menthol and thymol.

It is preferred that the composition is an enteric preparation, especially a capsule coated with an enteric coating. Enteric coatings are widely used in the pharmaceutical industry and are formed of substances which are relatively insoluble in the acid medium of the stomach but disintegrate in the medium of the small intestine. The capsule suitably is a hard gelatin capsule and a suitable enteric coating is cellulose acetate phthalate coating. Other suitable coatings include enteric coating lacquers based on polymeric methacrylates. Other enteric preparations can be used, such as enterically coated tablets containing the carminative substance in a microencapsulated form or loaded on a suitable excipient.

As mentioned previously, the preparation of the invention can be a rectal preparation. Examples of such preparations are enemas and, preferably suppositories. Suitably, the suppositories can be in the form of soft gelatin capsules enclosing the carminative substance.

Usually the carminative will be administered in a daily dose of 0.15 ml to 3.0 ml, especially 0.6 ml to 2.4 ml and particularly about 1.2 ml. The actual dose will vary from patient depending *inter alia* on the identity of the carminative, patient body weight, tolerance to the carminative and nature and degree of disorder being treated. It is convenient for each unit dose to contain 0.05 ml to 0.5 ml, especially 0.15 ml to 0.35 ml and particularly 0.2 ml to 0.3 ml of the carminative. By unit dose we mean that dose which is adapted or intended to be administered to the patient as a single unit, although several single units may be administered at the same time. Usually, the unit dose will be a discrete entity but this is not necessarily so, as in the case of an enema where sufficient preparation for several enemas may be provided in the same container (i.e. the container contains several unit doses) to be measured out as required.

The following is a description, by way of example only, of a presently preferred embodiment of the invention.

EXAMPLE

Self-locking hard gelatine capsules (size 2; 0.37 ml) available under the Trade Mark LOK-70 CAPS were each loaded manually with 0.15 ml Peppermint Oil B.P. dispensed from an automatic pipetting syringe. The filled capsules were placed in a coating tower where they were carried in a heated (55°C) air stream whilst being sprayed with an enteric coating solution. The coating solution had the following composition by weight:-

cellulose acetate phthalate	3%
diethyl phthalate	1%
silicone fluid (200 c.s.)	1%
ethyl acetate	30%
acetone	to 100%
Density of solution	870 mg/ml
Solids content	5.5%

An amount of 43.01 ml per 100 capsules was employed to provide a theoretical coating of 6 mg/cm², which is an excess of that theoretically required in order to allow for losses during the coating process.

It will be appreciated that the process described above is a small scale process devised for the purposes of preparing several hundred capsules for clinical evaluation. Production scale processes will almost certainly differ both in terms of the procedure employed and the relative proportions of the coating composition.

Enteric-coated capsules obtained as described above were subjected to the B.P. 1973 disintegration test for enteric-coated tablets (see page A123 British Pharmacopoeia 1973). The capsules were immersed in 0.06N Hydrochloric acid for a 3 hour period and during that time no disintegration took place. However, all the capsules disintegrated within 60 mins. when immersed in a standard solution of pH 6.8.

In order to evaluate *in vivo* disintegration, enterically-coated capsules were prepared as described above but filled with (a) a barium sulphate composition or (b) iodised poppyseed oil. Each of twelve patients chosen at random from patients attending a Barium Meal Clinic were given two of the barium sulphate capsules and two of the iodised poppy-seed oil capsules. The patients were subsequently examined radiologically. The average dissolution time was 143 minutes and the site of dissolution was in the region of the small bowel. The results indicate that the capsules pass intact through the stomach and greater part of the duodenum. Disintegration commenced at the distal end of the duodenum, continuing into the jejunum and finally the capsules releases its contents along the length of the ileum.

Thirtytwo patients attending a Colon Clinic showing symptoms consistent with irritable colon syndrome were admitted voluntarily to

an open clinical trial. The dose employed was one enteric coated peppermint oil capsule (prepared as described above and containing 0.15 ml Peppermint Oil B.P.) taken three times a day before meals. Clinical assessment of each patient was carried out after an initial treatment period of 14 days. If no side-effects were evident after this period and the patient had benefited from the treatment, it was continued for a further 14 days. After the second 14 day period, the overall patient response to the treatment was documented and comparison made with previous therapy. The treatment was continued indefinitely if beneficial. Thirteen patients showed excellent response and another twelve showed good response; the remaining seven did not find the treatment beneficial.

Only one patient showed any signs of toxic effects and this took the form of a hypersensitivity reaction to the menthol content of the oil, which reaction disappeared upon terminating the treatment. One other patient suffering from achlorhydria complained of heartburn and burping caused as a result of the capsules disintegrating in the abnormally high pH of the achlorhydric stomach. Some patients who found the treatment beneficial had previously been prescribed diphenoxylate, papaverine, dicyclomine or mebeverine without success.

The results of the test indicated that peppermint oil in enterically coated hard gelatine capsules is an acceptable and effective treatment of irritable colon syndrome.

CLAIMS

1. An enteric preparation (as hereinbefore defined) containing as a pharmacologically active ingredient a carminative essential oil (as hereinbefore defined) or a carminative component thereof.

2. A rectal preparation (as hereinbefore defined) containing as a pharmacologically active ingredient a carminative essential oil (as hereinbefore defined) or a carminative component thereof.

3. A preparation as claimed in Claim 2 which is a capsule coated with an enteric coating.

4. A preparation as claimed in Claim 3 wherein the capsule is a hard gelatin capsule.

5. A preparation as claimed in Claim 4 wherein the coating is a cellulose acetate phthalate coating.

6. A rectal preparation as claimed in Claim 2 in the form of a suppository.

7. A rectal preparation as claimed in Claim 6 wherein the suppository comprises a soft gelatin capsule enclosing the carminative ingredient.

8. A preparation as claimed in any one of the preceding Claims wherein the carminative essential oil contains menthol.

9. A preparation as claimed in Claim 8 wherein the essential oil is obtained from a

species of *Mentha*.

10. A preparation as claimed in Claim 9 wherein the essential oil is peppermint oil.

11. A preparation as claimed in any one of the preceding Claims containing 0.05 ml to 0.5 ml of the carminative substance per unit dose (as hereinbefore defined).

12. A preparation as claimed in Claim 11 wherein each unit dose contains 0.15 to 0.35 ml of the carminative substance.

13. A preparation as claimed in Claim 12 wherein each unit dose contains 0.2 to 0.3 ml of the carminative substance.

14. A preparation as claimed in any one of the preceding Claims which is in the form of discrete unit doses.

15. A preparation as claimed in Claim 1 and substantially as hereinbefore described in the Example.

16. Carminative essential oils (as hereinbefore defined) and their carminative components whenever used for selective administration of a carminative effect in the intestine.

17. Carminative essential oils (as hereinbefore defined) and their carminative components whenever used in the carminative treatment of intestinal disorders.

18. Carminative essential oils (as hereinbefore defined) and their carminative components for use in the carminative treatment of intestinal disorders.

19. Peppermint oil whenever used for selective administration of a carminative effect in the intestine.

20. Peppermint oil whenever used in the carminative treatment of intestinal disorders.

21. Peppermint oil for use in the carminative treatment of intestinal disorders.

Printed for Her Majesty's Stationery Office
by Burgess & Son (Abingdon) Ltd — 1979.
Published at The Patent Office, 25 Southampton Buildings,
London, WC2A 1AY, from which copies may be obtained.